PreMD Inc. Announces Second Quarter Conference Call
August 03 2006 - 10:00AM
PR Newswire (US)
TORONTO, Aug. 3 /PRNewswire-FirstCall/ -- Predictive medicine
company PreMD Inc. (TSX: PMD; Amex: PME) today announced it will
hold a conference call and webcast on Thursday, August 10, 2006 at
10 a.m. (ET) to review financial results and operating highlights
for the second quarter of fiscal 2006 ended June 30, 2006. The
event will be hosted by Dr. Brent Norton, President and CEO; Ron
Hosking, Vice President and CFO; and Sarah Borg-Olivier, Director,
Communications. To listen to the conference call, please dial (800)
866-5043. The event will be webcast live at
http://www.premdinc.com/ or http://www.newswire.ca/ and
subsequently archived for three months. A replay of the call will
be available until August 17, 2006 by dialing (416) 640-1917 or
(877) 289-8525 and entering access code 21199051 followed by the
number sign. About PreMD Inc. PreMD Inc. is a world leader in
predictive medicine, dedicated to developing rapid, non-invasive
tests for the early detection of life-threatening diseases. PreMD's
cardiovascular products, which are branded as PREVU(x) Skin Sterol
Test, are licensed worldwide to McNeil Consumer Healthcare. The
company's cancer tests include ColorectAlert(TM), LungAlert(TM) and
a breast cancer test. PreMD's head office is located in Toronto,
and its research and product development facility is at McMaster
University in Hamilton, Ontario. This news release contains
forward-looking statements, including the Company's expectations
related to future performance. Known and unknown risks and
uncertainties that could cause the Company's actual results to
differ materially from those in the forward-looking statements
include, among others: the successful and timely completion of
clinical studies; the successful development or marketing of the
Company's products and the competitiveness of the Company's
products if successfully commercialized; whether reimbursement for
the Company's products will be available and the potential impact
of reimbursement policies imposed by third-party payers on the
development, usage and pricing of the Company's products; the lack
of operating profit and availability of funds and resources to
pursue R&D projects and clinical trials; product liability; the
Company's reliance on third-party manufacturers; the ability of the
Company to take advantage of business opportunities; uncertainties
related to the Company's presentation of data to regulatory
authorities and the approval of marketing applications by
regulatory authorities; and general changes in economic conditions.
In addition, while the Company routinely obtains patents for its
products and technology, the protection offered by the Company's
patents and patent applications may be challenged, invalidated or
circumvented by its competitors and there can be no guarantee of
the Company's ability to obtain or maintain patent protection for
its products or product candidates. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S.
securities commissions, available at http://www.sedar.com/ and
http://www.sec.gov/, for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. The
Company is providing this information as of the date of this news
release and does not undertake any obligation to update any
forward-looking statements contained in this news release as a
result of new information, future events or otherwise. DATASOURCE:
PreMD Inc. CONTACT: Sarah Borg-Olivier, Director, Communications,
Tel: (416) 222-3449, Email:
Copyright